Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Research Areas > Neurological Disease > Alzheimer Disease

Alzheimer Disease

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC3114 Avagacestat (BMS-708163) Featured
BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.
More description
DC5061 GYKI 52466 dihydrochloride
GYKI 52466 dihydrochloride is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant.
More description
DC9915 PF04995274,PF 04995274 Featured
PF-04995274 is a 5-HT4 receptor partial agonist. It thought to act centrally as a pro-cognitive agent that being developed for the treatment of Alzheimer's disease (AD).
More description
DC11247 Nelonicline Featured
Nelonicline (ABT-126) is a potent, selective α7 nicotinic receptor (nAChR) partial agonist for the treatment of cognitive impairment with schizophrenia..
More description
DC11019 ASP3662 Featured
ASP3662 is a potent, selective, CNS-penetrable and orally active inhibitor of 11β-HSD1 with Ki of 5.3, 2.6 and 23 nM for human, mouse and rat 11β-HSD1, does not inhibit human 11β-HSD2 at 30 uM.
More description
DC11551 Elenbecestat Featured
Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..
More description
DC11105 Umibecestat Featured
beta-secretase inhibitor.
More description
DC4173 VX-745 Featured
VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively.
More description
DC9901 Verubecestat (MK-8931) Featured
MK-8931 is a BACE1 inhibitor. MK-8931 binds significantly to β-secretase.
More description
DC5036 LY-411575 Featured
LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.
More description
DC5053 LY2886721 Featured
LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.
More description
DC5180 LY2811376 Featured
LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.
More description
DC8277 E-2012 Featured
E 2012 is a potent γ-secretase modulator.
More description
DC10506 CPHPC(Miridesap) Featured
CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance.
More description
DC8338 Azeliragon(PF-04494700,TTP488) Featured
Azeliragon is an oral, small-molecule inhibitor of RAGE.
More description
DC8400 AZD3839 Featured
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
More description
DC9842 T0901317 Featured
T0901317 is a potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-α and LXR-β respectively).
More description
DC11208 TAK-071 Featured
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM.
More description
DC11301 ALZ-801 Featured
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.
More description
DC10217 TRx0237 (LMTX) mesylate Featured
TRx 0237 (LMTX™) mesylate is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia.
More description
DC11367 PF-04447943 Featured
PF-04447943 is a brain-permeable phosphodiesterase (PDE) inhibitor that is selective for PDE9A (IC50 = 12 nM) over other PDEs (IC50s = >940 nM) in enzymatic assays of second messenger hydrolysis.
More description
DC11389 BI 409306 Featured
BI 409306 is an inhibitor of phosphodisterase 9A(PDE9A).
More description
DC7496 Semagacestat Featured
Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM.
More description
DC10490 GIBH-130 Featured
GIBH-130 is a novel inhibitor of neuroinflammation effective in Alzheimer’s disease models.
More description
DC11038 Bryostatin 1 Featured
Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).
More description
DC9498 Xanomeline (oxalate)
Xanomeline(LY246708) is a selective M1 muscarinic receptor agonist.
More description
DCAPI1435 Rivastigmine tartrate
Rivastigmine hydrogen tartrate is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and Parkinson's disease.
More description
DC9329 (±)-Huperzine A
Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).
More description
DC9946 Lanabecestat(AZD3293,LY-3314814)
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease.
More description
DCJ-030 Galanthamine
>98%,Standard References
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X